Inhibitors allosteric site

Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, Koch U, Rowley M, De Francesco R, Mighaccio G, Card A (2005) Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280 29765-29770... 

The lack of structural similarity between a feedback inhibitor and the substrate for the enzyme whose activity it regulates suggests that these effectors are not isosteric with a substrate but allosteric ( occupy another space ). Jacques Monod therefore proposed the existence of allosteric sites that are physically distinct from the catalytic site. Allosteric enzymes thus are those whose activity at the active site may be modulated by the presence of effectors at an allosteric site. This hypothesis has been confirmed by many lines of evidence, including x-ray crystallography and site-directed mutagenesis, demonstrating the existence of spatially distinct active and allosteric sites on a variety of enzymes. 

Fig. 8. Allosteric sites in the mGluR 7TM. The chemical structures of the allosteric inhibitors MPEP, EM-TBPC, BAY36-7620, and CPCCOEt, and the allosteric potentiator Ro 67-7476 are given. The crucial residues or regions for the subtype selectivity of each of the compounds are stated and shown in a schematic illustration of the mGluRl 7TM viewed from the extracellular side of the cell membrane. The residues in mGluRl corresponding to those involved in MPEP binding to mGluR5 are also shown in the illustration.

The fullerene derivatives result to be noncompetitive inhibitors, meaning that, although the catalytic site of AChE could bind cationic fullerenes, the binding of C60 derivatives should take place in allosteric sites (Pastorin et al., 2006). Considering all these actions, with important biomedical applications, the question about selectivity naturally arises, but no answer has been proposed as yet. 

Enzymatic reactions can be impeded by the addition of exogenous molecules. This is how drugs are used to control biochemical reactions, and most drugs are used for inhibitory functions. Drugs may function as competitive inhibitors or as noncompetitive inhibitors. Competitive inhibitors compete with the substrates for binding to the active sites, whereas noncompetitive inhibitors bind to another location (allosteric site) but affect the active site and its consequential interactions with the substrates. Some drugs used as enzyme inhibitors are the following ... 

For example, experimental data might reveal that a novel enzyme inhibitor causes a concentration-dependent increase in Km, with no effect on and with Lineweaver-Burk plots indicative of competitive inhibition. Flowever, even at very high inhibitor concentrations and very low substrate concentrations, it is observed that the degree of inhibition levels off when some 60% of activity still remains. Furthermore, it has been confirmed that only one enzyme is present, and all appropriate blank rates have been accounted for. It is clear that full competitive inhibition cannot account for such observations because complete inhibition can be attained at infinitely high concentrations of a full competitive inhibitor. Thus, it is likely that the inhibitor binds to the enzyme at an allosteric site. 

In some cases, an inhibitor can bind to more than one site on an enzyme protein, with inhibition resulting from binding at multiple sites. Binding affinities at the two (or more) sites may be different, and mechanisms of inhibition may be dilferent for example, high-affinity inhibition might occur through an allosteric site and lower affinity inhibition through the active site. Analysis of such systems is complex and may require a combination of several of the approaches outlined later. 

The fact that ATP and CTP bind to the same site follows from the observation that adding ATP to the inhibited enzyme by CTP reduces or reverses the inhibition, presumably because ATP competes with CTP for the same site. The fact that CTP binds to an allosteric site (i.e., it is not a competitive inhibitor) follows from the so-called desensitization effect. Addition of mercurials [e.g., p-mercuribenzoate (PMB)] reduces or eliminates the inhibition by CTP. However, it has no effect on the enzymatic activity of ATCase, presumably because the mercurials affect the regulatory subunits but not the catalytic site. As for the mechanism of cooperativity (both positive and negative), it is known that CTP does induce changes in the quaternary structure of the enzyme. 

Fig. 16.3 Non-competitive inhibitor changes the actiue site of enzyme cfter binding at allosteric site.

This binding of inhibitor at allosteric site (Fig. 16.3) changes the shape of the active site in such a way that substrate cannot recognise it. 

Non-competitive inhibitors. These inhibitors bind to the enzyme or the enzyme-substrate complex at a site other than the active site. This results in a decrease in the maximum rate of reaction, but the substrate can still bind to the enzyme. An analogous concept is that of allosteric inhibition. The site of binding of an allosteric inhibitor is distinct from the substrate binding site. In this case, the inhibitor is not a steric analog of the substrate and instead binds to the allosteric site (the phenomenon was termed thus by Monod and Jacob). 

Metabolic activators and inhibitors are structurally dissimilar to substrates. These effectors exert regulatory control over catalysis by binding at an allosteric site quite distinct from the catalytic site. Such heterotropic interactions are mediated through conformational changes, often involving subunit interactions. Allosteric effectors can alter the catalytic rate by changing the apparent substrate affinity (K system) or by altering the... 

N., Nguyen- , N., Alaoui-Ismaili, M. H., Bethell, R. C., James, M. N. (2003) Nonnucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 278, 9489-9495. 

When fructose 2,6-bisphosphate binds to its allosteric site on PFK-1, it increases that enzyme s affinity for its substrate, fructose 6-phosphate, and reduces its affinity for the allosteric inhibitors ATP and citrate. At the physiological concentrations of its substrates ATP and fructose 6-phosphate and of its other positive and negative effectors (ATP, AMP, citrate), PFK-1 is virtually inactive in the absence of fructose 2,6-bisphosphate. Fructose 2,6-bisphosphate activates PFK-1 and stimulates glycolysis in liver and, at the same time, inhibits FBPase-1, thereby slowing gluconeogenesis. 

If an inhibitor binds not only to free enzyme but also to the enzyme substrate complex ES, inhibition is noncompetitive. In this case, S and I do not mutually exclude each other and both can be bound to the enzyme at the same time. Why does such an inhibitor slow an enzymatic reaction In most instances, the structure of the inhibitor does not show a close similarity to that of substrate, which suggests that the binding of inhibitors is at an allosteric site, that is, at a site other than that of the substrate. The inhibition of the enzyme may result from a distortion of the three-dimensional structure of the enzyme which is caused by the binding of the inhibitor. This distortion may be... 

Binding of a substance to an allosteric site sometimes has the effect of increasing the activity of an enzyme rather than inhibiting it. This may occur because the activator stabilizes the conformation that binds substrate best (Fig. 9-12). The quantitative treatment of such activation is similar to that of inhibition allosteric inhibitors and activators are often considered together and are referred to as modifiers or... 

We have already considered competitive inhibition which is obtained when K2 = 0 (and therefore K ds = 0). For this case, M is always an inhibitor and no activation is possible. Notice that the inhibition will appear competitive even if M binds at an allosteric site as in Fig. 9-13 or if the inhibited form does not react at all with substrate. Noncompetitive inhibition will be observed if ESM is formed but does not react, i.e., if /c4 = 0. Then the rate equation in reciprocal form will be given by Eq. 9-64. 

---